What is Perjeta (pertuzumab) and what is it used for?
Perjeta is a brand name for pertuzumab, an antibody that targets the HER2 receptor. It is used as part of treatment for HER2-positive cancers, most commonly HER2-positive breast cancer, where it is given together with other anticancer medicines (for example, trastuzumab and chemotherapy) to help reduce cancer growth and spread. [1]
How does Perjeta work compared with other HER2 drugs?
Perjeta works by binding to a different part of the HER2 receptor than some other HER2-targeted treatments. This helps it block signaling that tumors use to grow. In practice, it is often combined with trastuzumab because the two antibodies can act in complementary ways against HER2-driven cancer growth. [1]
Who typically gets Perjeta?
Perjeta is prescribed for people with HER2-positive tumors. In breast cancer settings, it is commonly used for HER2-positive disease in combination regimens, depending on the stage and treatment goal (for example, early-stage versus metastatic disease). [1]
What does Perjeta dosing and schedule look like?
Perjeta is administered by healthcare professionals, usually as an intravenous infusion. The exact dose and schedule depend on the cancer type, treatment setting, and what other drugs it is combined with. [1]
What side effects do people ask about with Perjeta?
Common questions include what side effects to expect and how serious they can be. In HER2-targeted antibody treatments, patients and clinicians also watch for heart-related effects (cardiac monitoring is commonly part of HER2 therapy), along with infusion-related reactions and other treatment-related adverse effects. Specific risks and monitoring plans vary by regimen. [1]
Can Perjeta be used in combination therapies?
Yes. Perjeta is commonly used with other HER2-targeted therapies and chemotherapy, depending on the indication. Combination use is central to how Perjeta is used in standard HER2-positive breast cancer regimens. [1]
Is Perjeta still under patent, and are biosimilars available?
Whether biosimilars are available and how long exclusivity lasts depends on jurisdiction and product-specific regulatory history. For accurate current availability, you would typically check your country’s medicine regulatory listings or pharmacy supply information. [1]
Sources
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta